Condition: Erectile Dysfunction · Sponsor: Pharmicell Co., Ltd.
This phase II clinical trial with safety follow-up is designed to evaluate the efficacy and safety of Cellgram-ED (autologous bone marrow-derived mesenchymal stem cells) administered via intracavernous injection in patients with erectile dysfunction after radical prostatectomy.
This description comes directly from the study's public registry record.
daeun jung · 82-2-3496-0134 · daeun4100@pharmicell.com
Always discuss trial participation with your own doctor first.
| Asan medical center | Seoul, South Korea | Recruiting |
| Ewha womans university medical center | Seoul, South Korea | Recruiting |
| Samsung medical center | Seoul, South Korea | Recruiting |
| Seoul ST. Mary's hospital | Seoul, South Korea | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07431008